Quince Therapeutics, Inc.
QNCX
$1.61
$0.010.63%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -34.81% | -40.07% | -2.64% | -467.52% | 9.02% |
| Total Depreciation and Amortization | -20.00% | -94.74% | -- | 4,300.00% | 135.29% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -6.04% | 32.40% | -378.10% | 2,276.66% | -49.58% |
| Change in Net Operating Assets | 354.78% | 658.00% | -92.41% | -807.46% | -150.16% |
| Cash from Operations | -14.94% | -24.25% | -50.68% | -128.35% | -134.04% |
| Capital Expenditure | -279.49% | -454.17% | -- | -- | 71.32% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 23.38% | 46.08% | 96.73% | 75.70% | 60.28% |
| Cash from Investing | 22.26% | 101.61% | 95.46% | 75.51% | 60.90% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -54.21% | -100.00% | -100.00% | 34.62% | 239.29% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -54.21% | -100.00% | -50,100.00% | 34.62% | 280.00% |
| Foreign Exchange rate Adjustments | -43.55% | 189.16% | -138.71% | -501.67% | 171.93% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 46.94% | 501.93% | -412.28% | 42.14% | -50.30% |